TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

2,018

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions
Coronary Stenoses
Interventions
DRUG

Tailored antithrombotic strategy

Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months

DRUG

Conventional antithrombotic strategy

Clopidogrel + aspirin for 12months

Trial Locations (22)

Unknown

Hallym University Sacred Heart Hospital, Anyang

Soon Chun Hyang University Hospital Bucheon, Bucheon-si

Gyeongsang National University Changwon Hospital, Changwon

Chungbuk National University Hospital, Cheonju

Gangwon National Univ. Hospital, Chuncheon

Daegu Catholic University Medical Center, Daegu

Keimyung University Dongsan Medical Center, Daegu

Gangneung Asan Hospital, Gangneung

Chonnam National University Hospital, Gwangju

Dong-A Medical Center, Pusan

Inje University Pusan Paik Hospital, Pusan

Pusan National University Hospital, Pusan

Bundang CHA Hospital, Seongnam

Seoul university Bundang hospital, Seongnam-si

Asan Medical Center, Seoul

Chung-Ang University Hospital, Seoul

Korea University Guro Hospital, Seoul

The Catholic Univ. of Korea Eunpyeong St. Mary's hospital, Seoul

The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul

St.Carollo Hospital, Suncheon

The Catholic University of Korea, ST. Mary's Hospital, Suwon

Ulsan University Hospital, Ulsan

All Listed Sponsors
collaborator

CardioVascular Research Foundation, Korea

OTHER

lead

Duk-Woo Park, MD

OTHER

NCT03465644 - TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI | Biotech Hunter | Biotech Hunter